Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients

Mostrar otras versiones (1)

The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being...

Descripción completa

Detalles Bibliográficos
Autores principales: Luchsinger, Larry L., Ransegnola, Brett, Jin, Daniel, Muecksch, Frauke, Weisblum, Yiska, Bao, Weili, George, Parakkal Jovvian, Rodriguez, Marilis, Tricoche, Nancy, Schmidt, Fabian, Gao, Chengjie, Jawahar, Shabnam, Pal, Mouli, Schnall, Emily, Zhang, Huan, Strauss, Donna, Yazdanbakhsh, Karina, Hillyer, Christopher D., Bieniasz, Paul D., Hatziioannou, Theodora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302251/
https://www.ncbi.nlm.nih.gov/pubmed/32577675
http://dx.doi.org/10.1101/2020.06.08.20124792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302251/
https://www.ncbi.nlm.nih.gov/pubmed/32577675
http://dx.doi.org/10.1101/2020.06.08.20124792

Ejemplares similares